Vol 3 (December 2020): Precision Cancer Medicine

Checkpoint inhibitors first in patients with metastatic non-small cell lung cancer harboring BRAF^V600E mutation with PD-L1 90%—a debate in a niche population

CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC

Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”

ADAURA: a definitive answer to the wrong question

Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

Use of 3D-planning and tantalum in revision total hip arthroplasty after failed iliac bone allograft for Ewing sarcoma: a case report

Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient: a case report

Feasibility of ultra-central stereotactic ablative irradiation in lung cancer undergoing nivolumab: a case report

Micrometastatic breast cancer presenting as abnormal uterine bleeding: case report

A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications

Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors

On opposing ideas